News
![IpsenaLogo](https://pharmaphorum.com/wp-content/uploads/2016/07/IpsenaLogo.jpg)
Ipsen tries again in Parkinson's disease with $363m IRLAB de...
French drugmaker Ipsen has made another foray into the Parkinson's disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden's IRLAB for $28 million upfront.